Article

QLT lowers verteporfin cost after CMS cuts reimbursement

Toronto-QLT Inc. is temporarily lowering the price of verteporfin (Visudyne, Novartis and QLT Inc.) by $55 after the Centers for Medicare & Medicaid Services (CMS) lowered the amount for which it would reimburse physicians.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Vicki Chan, MD, shares pearls for leveraging the power of social media in health care
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
Related Content
(Image credit: AdobeStock/iQoncept)
March 26th 2025

Beyond mentoring: The power of sponsorship and advocacy in ophthalmology

Commercial real estate and your practice, part two with Colin Carr
May 21st 2022

Commercial real estate and your practice, part two with Colin Carr

AAO 2024: One simple change to boost sustainability in eye clinics: Stop discarding eye drops before they expire
October 17th 2024

AAO 2024: One simple change to boost sustainability in eye clinics: Stop discarding eye drops before they expire

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)
May 12th 2022

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

Mental health and ophthalmology
May 17th 2024

Mental health and ophthalmology

Prevent Blindness kicks off ‘It Started With an Eye Exam’
May 16th 2024

Prevent Blindness kicks off ‘It Started With an Eye Exam’

© 2025 MJH Life Sciences

All rights reserved.